Zogenix, Inc. (ZGNX)

NASDAQ: ZGNX · IEX Real-Time Price · USD
16.10 0.17 (1.07%)
Jan 18, 2022 1:28 PM EST - Market open
Market Cap901.47M
Revenue (ttm)63.59M
Net Income (ttm)-242.70M
Shares Out55.99M
EPS (ttm)-4.35
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume841,628
Open15.85
Previous Close15.93
Day's Range15.70 - 16.86
52-Week Range11.03 - 23.69
Beta1.29
AnalystsBuy
Price Target36.20 (+124.8%)
Earnings DateNov 4, 2021

About ZGNX

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also...

IndustryPharmaceuticals
IPO DateNov 23, 2010
CEOStephen Farr
Employees218
Stock ExchangeNASDAQ
Ticker SymbolZGNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for Zogenix stock is "Buy." The 12-month stock price forecast is 36.20, which is an increase of 124.84% from the latest price.

Price Target
$36.20
(124.84% upside)
Analyst Consensus: Buy

News

Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures As...

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) t...

4 weeks ago - GlobeNewsWire

Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (...

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submit...

4 weeks ago - GlobeNewsWire

Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to nine (9) new...

1 month ago - GlobeNewsWire

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome Data add to the growing body of evidence supporting the efficacy and ...

1 month ago - GlobeNewsWire

Why Are Zogenix's Shares Gaining Today?

The FDA has granted Priority Review to Zogenix Inc's (NASDAQ: ZGNX) supplemental marketing application seeking approval for Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) childhood-onset epile...

1 month ago - Benzinga

Zogenix to Participate in Two Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team wi...

2 months ago - GlobeNewsWire

4 of the Fastest-Growing Stocks on the Planet Through 2024

Wall Street projects aggregate sales growth of 509% to 3,324% for these stocks.

Other symbols:COINNVAX
2 months ago - The Motley Fool

Zogenix (ZGNX) Reports Q3 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.33% and 0.49%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Zogenix Q3 Earnings

Zogenix (NASDAQ:ZGNX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

2 months ago - Benzinga

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy

Zogenix Inc (NASDAQ: ZGNX) has announced interim data from an ongoing 12-month Phase 3 open-label extension (OLE) study of Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS). Data showed that fenf...

3 months ago - Benzinga

New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrom...

EMERYVILLE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data from an interim analysis of an o...

3 months ago - GlobeNewsWire

Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?

Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 months ago - Zacks Investment Research

5 Stocks With 195% to 467% Upside, According to Wall Street

If these high-water price targets come to fruition, investors will be all smiles.

Other symbols:AMRNICPTINOPLUG
4 months ago - The Motley Fool

3 Biotech Stocks Wall Street Expects to Double Soon

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

Other symbols:AXSMCMPS
4 months ago - The Motley Fool

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

These fast-paced companies should generate jaw-dropping revenue growth over the next three years.

Other symbols:JAZZMRNA
4 months ago - The Motley Fool

Zogenix (ZGNX) Reports Q2 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -12.90% and 10.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Zogenix Q2 Earnings

Shares of Zogenix (NASDAQ:ZGNX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 9.38% year over year to ($1.05), which missed the estim...

5 months ago - Benzinga

Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results

EMERYVILLE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results ...

5 months ago - GlobeNewsWire

Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Fa...

5 months ago - GlobeNewsWire

VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Ep...

EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of  VIP Sibli...

6 months ago - GlobeNewsWire

Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Far...

8 months ago - GlobeNewsWire

Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates

Zogenix (ZGNX) delivered earnings and revenue surprises of -2.04% and 9.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Recap: Zogenix Q1 Earnings

Shares of Zogenix (NASDAQ:ZGNX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 85.19% year over year to ($1.00), which beat the est...

8 months ago - Benzinga

Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results

EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results f...

8 months ago - GlobeNewsWire